TP53 and glioblastoma: The VAF of this TP53 mutation increased from 26.7% in GBM to 50.8% in SGS (Figure 3D), indicating that the cellular prevalence of TP53 mutation increased from being present in approximately half of the tumor cells to virtually all of the tumor cells.